Handa Pharmaceuticals, Inc. (TPEX:6620)

Taiwan · Delayed Price · Currency is TWD

81.80

+7.40 (9.95%)

Jun 18, 2026, 1:23 PM CST

-3.42% (1Y)

Market Cap	13.62B +0.8%
Revenue (ttm)	1.76B +121.4%
Net Income	780.80M +94.8%
EPS	4.86 +72.6%
Shares Out	166.53M
PE Ratio	16.84
Forward PE	n/a
Dividend	2.00 (2.44%)
Ex-Dividend Date	Jul 6, 2026

Volume	1,676,096
Open	74.60
Previous Close	74.40
Day's Range	74.60 - 81.80
52-Week Range	64.10 - 154.00
Beta	0.73
Analysts	Strong Buy
Price Target	200.00 (+144.5%)
Earnings Date	Aug 13, 2026

About Handa Pharmaceuticals

Handa Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development of drugs for various diseases in the United States. The company offers ONCORE, a proprietary drug delivery technology that was developed to improve the patient compliance and safety of the tyrosine kinase inhibitor of oncology drugs; Phyrago, an oral kinase inhibitor used to treat chronic myeloid leukemia and acute lymphoblastic leukemia; Tascenso ODT for the treatment of multiple sclerosis; and HND-033, HND-039, and HND-027 for oncology diseases. It als... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 2014

Employees 13

Stock Exchange Taipei Exchange

Ticker Symbol 6620

Full Company Profile

Financial Performance

In 2025, Handa Pharmaceuticals's revenue was 1.73 billion, an increase of 108.17% compared to the previous year's 830.67 million. Earnings were 749.77 million, an increase of 58.60%.

Financial Statements